title: Treatment results of Hodgkin's disease in Indian children.
abstract: This is a retrospective study of Hodgkin's disease in children less than 15 years of age who were registered at Tata Memorial Hospital in India from January 1985 through December 1990. Clinicopathologic characteristics and response were evaluated in 147 patients and survival was calculated in 187. There were 126 boys and 21 girls (6:1). All patients were treated with combination chemotherapy and involved field radiotherapy. The COPP schedule was given to 108 patients. COPP/ABVD to 33, and ABVD to 6. Ninety-three patients (63%) had stage I or II disease and 54 (37%) had stage III or IV disease. B symptoms were observed in 65 patients (56%) and bulky disease in 40 (27%). Histologically, the most common subtype was mixed cellularity, seen in 95 patients (65%). Complete response was observed in 136 (89%), partial response in 6 (4%), and there were 4 treatment-related deaths. Relapse has been observed in 11%. Seven-year actuarial survival was 73% and event-free survival was 64%. Median survival has not yet been reached, with a median follow-up of 36 months.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Parel, Bombay, India.
authors.forename: G
authors.initials: G
authors.lastname: Kapoor
authors.forename: S H
authors.initials: SH
authors.lastname: Advani
authors.forename: K A
authors.initials: KA
authors.lastname: Dinshaw
authors.forename: M A
authors.initials: MA
authors.lastname: Muckaden
authors.forename: C S
authors.initials: CS
authors.lastname: Soman
authors.forename: T K
authors.initials: TK
authors.lastname: Saikia
authors.forename: R
authors.initials: R
authors.lastname: Gopal
authors.forename: C N
authors.initials: CN
authors.lastname: Nair
authors.forename: P A
authors.initials: PA
authors.lastname: Kurkure
authors.forename: S K
authors.initials: SK
authors.lastname: Pai
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007223:Infant; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012189:Retrospective Studies; D012737:Sex Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone